source
- AbCellera's Phase 2 hot flash trial beats aggressive upside target, challenging Astellas and BayerAbCellera announced that its Phase 2 study of ABCL635, an antibody that blocks the NK3R receptor, met its primary endpoint in postmenopausal women with hot flashes. The trial enrolled 92 participan…
- AbCellera reports striking Phase 2 results for hot-flash treatment, shares jump 31%AbCellera Biologics announced positive Phase 2 data for its neurokinin-3 receptor antagonist aimed at relieving vasomotor symptoms such as hot flashes. The company described the results as strikin…Endpoints · 22h agoPositive readoutPositive